
Opinion|Videos|September 4, 2024
Ravulizumab Long-Term Data and Management of NMOSD
Author(s)Michael Levy, MD, PhD
This discussion examines the 138-week data on ravulizumab for NMOSD, focusing on long-term relapse rates, and share practical tips for effective NMOSD management in clinical settings.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- The 138-week data for ravulizumab, the most recently approved neuromyelitis optica spectrum disorder (NMOSD) treatment, was presented at the 2024 American Academy of Neurology Annual Meeting. What do we know about relapses while on ravulizumab in the long term?
- Please share practical tips for management of NMOSD in the clinic.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Roche Unveils PrevenTRON, a Phase 3 Prevention Trial of Trontinemab in Cognitively Unimpaired Individuals at High Risk of Alzheimer Decline
2
Alzheimer's Association Launches PROTECT-Cog Combination Prevention Trial
3
Sanofi's Oral TREM2 Agonist SAR448851 Advances to Phase 2 TREMHANCE Trial in Early Alzheimer Disease
4
Building the Foundation for Earlier Alzheimer Disease Diagnosis
5















